Patent intelligence · US
US 12065493
Anti-MICA/B antibodies that block MICA/B shedding and methods of use
Anti-MICA/B antibodies that block MICA/B shedding and methods of use
Patent details — US 12065493
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 20, 2024
- Expiration
- Aug 15, 2044
- Applicant
- Cullinan Mica Corporation
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 12065493 (Anti-MICA/B antibodies that block MICA/B shedding and methods of use) is held by Cullinan Mica Corporation. Status: granted. Granted Aug 20, 2024. Expires Aug 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cullinan Mica Corporation
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from Cullinan Mica Corporation
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12065493?
US 12065493 (Anti-MICA/B antibodies that block MICA/B shedding and methods of use) is held by Cullinan Mica Corporation. Status: granted. Granted Aug 20, 2024. Expires Aug 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12065493?
Cullinan Mica Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12065493 expire?
Our index shows an expiration date of Aug 15, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.